BioSpace News Archive

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced data from a poster presentation at the 65th ASH Annual Meeting and Exposition, which took place from December 9-12th, 2023 in San Diego, California.

Astiva Health Inc., a fast-growing Medicare Advantage Prescription Drug (MAPD) health plan dedicated to reshaping personalized and comprehensive healthcare, announced today that it has started the process of registering its common shares on the Nasdaq Global Select.

Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting.

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care.

Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a national leading pharmacy chain to stock ELYXYB®.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) is pleased to announce a non-brokered private placement financing (the “Offering”) of 1,250,000 units of the Company (the “Units”), for aggregate gross proceeds of $500,000.

Tourmaline Bio, Inc. announced that Tourmaline has been added to the NASDAQ Biotechnology Index, effective prior to market open, Monday, December 18, 2023.

Verrica Pharmaceuticals Inc. announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum in Japan.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer’s disease (AD), those individuals not yet showing symptoms.

Sanofi announced that its Q4 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.